Seven Grand Managers LLC Purchases New Position in Guardant Health, Inc. $GH

Posted by on May 28th, 2026

Seven Grand Managers LLC purchased a new stake in shares of Guardant Health, Inc. (NASDAQ:GH – Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 40,000 shares of the company’s stock, valued at approximately $4,086,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in GH. Alyeska Investment Group L.P. bought a new stake in shares of Guardant Health during the 3rd quarter valued at approximately $114,421,000. Franklin Resources Inc. grew its holdings in Guardant Health by 26.1% during the 3rd quarter. Franklin Resources Inc. now owns 2,926,315 shares of the company’s stock worth $182,836,000 after acquiring an additional 606,368 shares during the last quarter. Qube Research & Technologies Ltd grew its holdings in Guardant Health by 124.3% during the 3rd quarter. Qube Research & Technologies Ltd now owns 570,095 shares of the company’s stock worth $35,620,000 after acquiring an additional 315,896 shares during the last quarter. Federated Hermes Inc. grew its holdings in Guardant Health by 21.2% during the 3rd quarter. Federated Hermes Inc. now owns 1,776,369 shares of the company’s stock worth $110,988,000 after acquiring an additional 310,931 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in Guardant Health by 9.4% during the 4th quarter. Geode Capital Management LLC now owns 3,213,657 shares of the company’s stock worth $328,297,000 after acquiring an additional 277,001 shares during the last quarter. 92.60% of the stock is owned by institutional investors.

Guardant Health Stock Performance

Shares of NASDAQ GH opened at $127.51 on Thursday. The company has a market capitalization of $16.91 billion, a P/E ratio of -37.61 and a beta of 1.48. Guardant Health, Inc. has a 52-week low of $37.73 and a 52-week high of $128.00. The company’s 50 day moving average price is $93.34 and its 200-day moving average price is $99.48.

Insider Transactions at Guardant Health

In other news, Director Ian T. Clark sold 6,876 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The shares were sold at an average price of $106.90, for a total value of $735,044.40. Following the transaction, the director owned 2,975 shares in the company, valued at approximately $318,027.50. The trade was a 69.80% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Amirali Talasaz sold 210,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The stock was sold at an average price of $109.89, for a total transaction of $23,076,900.00. Following the completion of the transaction, the chief executive officer owned 1,886,504 shares in the company, valued at $207,307,924.56. This trade represents a 10.02% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 321,244 shares of company stock worth $34,775,166. Company insiders own 5.60% of the company’s stock.

Analyst Upgrades and Downgrades

GH has been the topic of a number of research reports. TD Cowen reissued a “buy” rating on shares of Guardant Health in a report on Thursday, May 21st. Canaccord Genuity Group boosted their target price on shares of Guardant Health from $125.00 to $135.00 and gave the stock a “buy” rating in a report on Friday, February 20th. Wells Fargo & Company boosted their target price on shares of Guardant Health from $120.00 to $125.00 and gave the stock an “overweight” rating in a report on Friday, February 20th. Robert W. Baird initiated coverage on shares of Guardant Health in a report on Tuesday, February 17th. They set an “outperform” rating and a $120.00 target price on the stock. Finally, Barclays boosted their target price on shares of Guardant Health from $115.00 to $120.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. Nineteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $129.79.

Get Our Latest Research Report on GH

Guardant Health Profile

(Free Report)

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.

Featured Stories

Want to see what other hedge funds are holding GH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Guardant Health, Inc. (NASDAQ:GH – Free Report).

Institutional Ownership by Quarter for Guardant Health (NASDAQ:GH)

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.